Last reviewed · How we verify
Celecoxib 100 mg
Celecoxib 100 mg, developed by Charles University in the Czech Republic, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which currently shields it from generic competition. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Celecoxib 100 mg |
|---|---|
| Also known as | Celebrex 100 mg, Celecoxib 100mg capsule |
| Sponsor | Charles University, Czech Republic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas (PHASE1)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors (PHASE2)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain (NA)
- A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine (PHASE4)
- Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain (NA)
- Triple Negative Breast Cancer and Celecoxib. Pilot Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib 100 mg CI brief — competitive landscape report
- Celecoxib 100 mg updates RSS · CI watch RSS
- Charles University, Czech Republic portfolio CI